Paul G. Richardson, MD
Clinical Program Leader and Director of Clinical Research
Jerome Lipper Multiple Myeloma Center
Institute Physician
RJ Corman Professor of Medicine
Harvard Medical School
Boston, MA
Jerome Lipper Multiple Myeloma Center
Institute Physician
RJ Corman Professor of Medicine
Harvard Medical School
Boston, MA
Authored Items
Faculty Perspectives: Optimizing Clinical Outcomes and Value-Based Management in Multiple Myeloma—The Role of Isatuximab
The ICARIA-MM and IKEMA-MM phase 3 trials have been pivotal in identifying Isa’s high efficacy and favorable tolerability profile as a notable therapy in the role of RRMM management. Recently, there have been additional updates illustrating the unique effects of Isa. This article focuses on these updates and how they may inform the role of Isa in the treatment of MM. Read More ›
Faculty Perspectives: The Evolving Clinical and Pharmacoeconomic Impact of Isatuximab in Multiple Myeloma Management
Isatuximab is 1 of the 2 FDA-approved anti-CD38 monoclonal antibodies used to treat patients with multiple myeloma. Read More ›